[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531638":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":14,"locations":20,"responsibleParty":48,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Fudan University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"High risk group",null,"This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.",{"label":13,"type":10,"description":11,"interventionNames":10},"Low risk group",[15],{"name":16,"role":17,"phone":18,"phoneExt":10,"email":19},"Xiao Chu","CONTACT","15821383376","chuxiao@sibs.ac.cn",[21,41],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":30,"coordinates":31},"Point",[32,33],121.45806,31.22222,{"lat":33,"lon":32},[36,40],{"name":37,"role":17,"phone":38,"phoneExt":10,"email":39},"Zhengfei Zhu, MD","+86 18017312901","fuscczzf@163.com",{"name":16,"role":17,"phone":18,"phoneExt":10,"email":19},{"facility":22,"status":23,"city":24,"state":10,"zip":10,"country":27,"countryCode":28,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},{"type":30,"coordinates":43},[32,33],{"lat":33,"lon":32},[46],{"name":37,"role":17,"phone":47,"phoneExt":10,"email":39},"+86-18017312901",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhengfei Zhu","Professor","100531638","predicting-tumor-metastasis-by-employing-a-target-organprimary-lesion-fusion-radiomics-model-100531638",false,"NCT06202404","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model: a Prospective Observational Trial","Inclusion Criteria:\n\n1. ECOG performance status score 0-2;\n2. Histologically or cytologically confirmed stage III-IV NSCLC;\n3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR\u002FALK\u002FROS1\u002FKRAS\u002FMET) should be performed;\n4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR\u002FCT for colorectal cancer, and chest CT for breast cancer);\n5. No target organ metastasis on baseline imaging (no brain\u002Fliver\u002Flung metastasis for lung cancer\u002Fcolorectal cancer\u002Fbreast cancer, respectively);\n6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;\n7. Regular follow-up during and after treatment;\n8. Life expectancy ≥6 months;\n\nExclusion Criteria:\n\n1. Patients with indeterminate pathological type;\n2. Patients without baseline imaging data before treatment;\n3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer\u002Fcolorectal cancer\u002Fbreast cancer corresponding to brain\u002Fliver\u002Flung metastasis);\n4. patients who cannot or refuse to receive regular imaging follow-up;\n5. Combined history of other malignant tumors;\n6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,\n7. Lactating or pregnant women;\n8. Receiving other long-term medications that may affect disease progression as assessed by a physician.","ALL","18 Years","75 Years",{"count":63,"type":64},166,"ESTIMATED","OBSERVATIONAL","A pre-metastatic target organ\u002Fprimary lesion fusion radiomics model was developed based on the \"soil-seed\" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ\u002Fprimary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.",[68,69],"Metastasis","Predictive Cancer Model",[71,72,73],"metastasis","radiomics","seed and soil theory","2024-02-08",{"date":76,"type":77},"2024-02-09","ACTUAL",{"date":79,"type":77},"2024-01-01",{"date":81,"type":64},"2027-12",{"name":5,"class":6},2]